About Dr Nicolas Dzamko

My team is interested in understanding the biological processes underlying neurodegenerative disease

My expertise is in understanding how enzymes and signalling pathways are perturbed in human disease. This gives clues to which biological processes may be impaired and gives ideas on how to fix things.

Dr Dzamko obtained his PhD from the University of Melbourne in 2008, and has since worked at the MRC protein phosphorylation unit at the University of Dundee, and at the University of NSW. Currently Dr Dzamko is a senior research fellow at the University of Sydney. Dr Dzamko has made a significant contribution to the Parkinson's disease field including contributing to the discovery of the first small molecule inhibitor of the genetically implicated LRRK2 protein. Dr Dzamko also discovered and patented a pharmacological biomarker for LRRK2, which is now being used in clinical trials of the latest LRRK2 inhibitors. Other notable contributions include the discovery that activation of inflammatory pathways on neurons can lead to alpha-synuclein accumulation, and that GBA activity is decreased in peripheral immune cells from Parkinson's disease patients. Dr Dzamko has received substantial funding from the NHMRC and Michael J Fox Foundation for his work on Parkinson's disease and has supervised a number of honours and PhD students.

For a comprehensive list of Dr Nicolas's publications, please visit his Sydney Medical School profile page.

Selected publications

CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK.
Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR. Nat Med. 2006 May;12(5):541-8. 

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ. Biochem J. 2010 Sep 15;430(3):405-13.

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Deng* X, Dzamko* N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Nat Chem Biol. 2011 Apr;7(4):203-5. 

The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray N, Cohen P, Pedrioli P, Clark K, Alessi DR. PLoS One. 2012;7(6):e39132. 

Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. Dzamko N, Rowe DB, Halliday GM. Mov Disord. 2016; 31(6):889-97.

Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Perera G, Renola M, Rowe D.B, Halliday G.M, Dzamko N. Scientific Reports. 2016; 6:31391

Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. Dzamko N, Gysbers A, Perera G, Bahar A, Shankar A, Gao J, Fu Y, Halliday G.M. Acta Neuropathologica. 2017; 133(2):303-319Reduced

LRRK2 in association with retromer dysfunction in brain tissue from LRRK2 mutation carriers. Zhao Y, Perera G, Fujigasaki J, Mash D, Vonsattel JP, Uchino A, Hasegawa K, Nichols R, Holton L, Murayama S, Dzamko N, Halliday G. Brain. 2018; 141(2):486-495

Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Zhao Y, Keshiya S, Atashrazm F, Gao J, Ittner L.M, Alessi D.R, Halliday G.M, Fu Y, Dzamko N. Neurobiol Dis. 2018; 5(120):76-87

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease.
Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, Kim W, Kwok JB, Lewis SJG, Halliday GM, Dzamko N. Scientific Reports 2018; 8(1):15446.